Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases June 19, 2020 – Posted in: Tiziana Life Sciences (TILS)

Friday 19th June, 2020 Tiziana Life Sciences plc  (“Tiziana” or the “Company”) Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases ·    First-ever granted patent on oral administration of anti-CD3 monoclonal antibodies for immunotherapies ·    Transformational oral formulation technologies applicable to other antibodies   This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. New York/London, 19 June 2020…

Continue reading